TY - JOUR
T1 - Systematic Review and Meta-Analysis
T2 - Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection
AU - Sehgal, Kanika
AU - Zandvakili, Inuk
AU - Tariq, Raseen
AU - Pardi, Darrell S.
AU - Khanna, Sahil
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Background: Vancomycin is the drug of choice for treating Clostridioides difficile infection (CDI). We compare CDI resolution with vancomycin taper, pulse, and taper-and-pulse regimens. Methods: We searched for Medline, Embase, Cochrane, and Scopus through October 9th, 2020. Taper regimen was defined as dose reduction over time; pulse was a regimen less frequent than daily. Studies assessing CDI resolution rates were included. Meta-analyses for resolution rates were performed using weighted proportion ratios (WPR). Results: Ten studies with 675 patients treated with vancomycin regimens were included. Resolution rates were 83% (212/266, 95% CI 69–94%, I2 = 85%) for taper-and-pulse, 68% (264/383, 95% CI 57–78%, I2 = 72%) for taper alone, and 54% (11/26 95% CI 0–100%, I2 = 86%) for pulse alone regimens. Taper-and-pulse was superior to taper alone (WPR 83% vs 68%, p < 0.0001) and pulse alone (WPR 83% vs 54%, p < 0.0004), no significant difference between taper alone or pulse alone (WPR 68% vs 54%, p = 0.1). Conclusions: Limitations of our analysis are a small number of included studies and heterogeneity. Vancomycin taper-and-pulse seems superior to pulse alone or taper alone for recurrent CDI. A randomized controlled trial comparing vancomycin taper-and-pulse to fidaxomicin and microbiome restoration is needed.
AB - Background: Vancomycin is the drug of choice for treating Clostridioides difficile infection (CDI). We compare CDI resolution with vancomycin taper, pulse, and taper-and-pulse regimens. Methods: We searched for Medline, Embase, Cochrane, and Scopus through October 9th, 2020. Taper regimen was defined as dose reduction over time; pulse was a regimen less frequent than daily. Studies assessing CDI resolution rates were included. Meta-analyses for resolution rates were performed using weighted proportion ratios (WPR). Results: Ten studies with 675 patients treated with vancomycin regimens were included. Resolution rates were 83% (212/266, 95% CI 69–94%, I2 = 85%) for taper-and-pulse, 68% (264/383, 95% CI 57–78%, I2 = 72%) for taper alone, and 54% (11/26 95% CI 0–100%, I2 = 86%) for pulse alone regimens. Taper-and-pulse was superior to taper alone (WPR 83% vs 68%, p < 0.0001) and pulse alone (WPR 83% vs 54%, p < 0.0004), no significant difference between taper alone or pulse alone (WPR 68% vs 54%, p = 0.1). Conclusions: Limitations of our analysis are a small number of included studies and heterogeneity. Vancomycin taper-and-pulse seems superior to pulse alone or taper alone for recurrent CDI. A randomized controlled trial comparing vancomycin taper-and-pulse to fidaxomicin and microbiome restoration is needed.
KW - Clostridioides difficile
KW - pulse
KW - recurrence
KW - taper
KW - vancomycin
UR - http://www.scopus.com/inward/record.url?scp=85118436394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118436394&partnerID=8YFLogxK
U2 - 10.1080/14787210.2022.1997588
DO - 10.1080/14787210.2022.1997588
M3 - Article
C2 - 34693838
AN - SCOPUS:85118436394
SN - 1478-7210
VL - 20
SP - 577
EP - 583
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
IS - 4
ER -